EGFR and KRAS somatic mutations, previously detected by SS, were confirmed by both pipelines either in SF and matched FFPE, validating the high specificity of the Ion AmpliSeq Colon and Lung Cancer panel for the identification of these mutations. The gene discussed is KRAS; the disease is lung carcinoma.